Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
IPO Year: 2014
Exchange: NASDAQ
Website: protaratx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/16/2025 | $12.00 | Sector Outperform | Scotiabank |
| 3/14/2025 | Overweight | Cantor Fitzgerald | |
| 7/10/2023 | $22.00 | Buy | Guggenheim |
| 11/8/2021 | $32.00 → $34.00 | Outperform | Oppenheimer |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)
8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
424B5 - Protara Therapeutics, Inc. (0001359931) (Filer)
424B5 - Protara Therapeutics, Inc. (0001359931) (Filer)
8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
Fastest customizable press release news feed in the world
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,043,479 shares of its common stock at a public offering price of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering were approximately $75 million before deducting underwriting discounts and commissions and offeri
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,043,479 shares of its common stock at a price to the public of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares in the offering are being sold by Protara. The gross proceeds from the offering are expected to be approximately $75 million
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of $75 million in aggregate of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be offered by Protara. In addition, Protara expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the
TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects to complete enrollment of the BCG-Unre
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The Company will also provide an update on feedback from the U.S. Food and Drug Administrat
80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability profile with no serious adverse events reportedCompany to host conference call and webcast featuring Key Opinion Leader Dr. Jesse Jones at 8:30 a.m. ET NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive interim results from its ongoing Phase 2 open-label S
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 19, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label STARBORN-1 trial assessing TARA-002, the Company's investigational cell-based therapy, in pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs). The live event and accompanying slides can be accessed by visiting https://protara-therapeutics-update-call.open-exchange.net/registration
Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to present interim analysis from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing ADVANCED-2 trial in 1Q 2026Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support now expected by year-end 2025Cash, cash equivalents and investments of approximately $134 million as of September 30, 2025, expected to support planned operations into mid-2027 NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"),
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has been named a BioSpace 2026 Best Place to Work. "Protara is thrilled to be recognized as one of the most sought-after biotech employers in the life sciences community," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "Our colleagues are crucial to every aspect of our success, and this award is a reflection of our team's commitment to fostering a vibrant culture that attracts top talent and inspires team members to make a meaningful impact. I would
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee. The Compensation Committee of Protara's Board of Directors approved an aggregate of 6,200 stock option awards and 3,100 RSU awards to one new employee from the Inducement Plan, as inducements material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on October 1, 2025
Scotiabank initiated coverage of Protara Therapeutics with a rating of Sector Outperform and set a new price target of $12.00
Cantor Fitzgerald initiated coverage of Protara Therapeutics with a rating of Overweight
Guggenheim resumed coverage of Protara Therapeutics with a rating of Buy and set a new price target of $22.00
Oppenheimer reiterated coverage of Protara Therapeutics with a rating of Outperform and set a new price target of $34.00 from $32.00 previously
HC Wainwright & Co. initiated coverage of Protara Therapeutics with a rating of Buy and set a new price target of $40.00
Oppenheimer initiated coverage of Protara Therapeutics with a rating of Outperform and set a new price target of $43.00
This live feed shows all institutional transactions in real time.
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
Live finance-specific insights
TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects to complete enrollment of the BCG-Unre
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The Company will also provide an update on feedback from the U.S. Food and Drug Administrat
80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability profile with no serious adverse events reportedCompany to host conference call and webcast featuring Key Opinion Leader Dr. Jesse Jones at 8:30 a.m. ET NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive interim results from its ongoing Phase 2 open-label S
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 19, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label STARBORN-1 trial assessing TARA-002, the Company's investigational cell-based therapy, in pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs). The live event and accompanying slides can be accessed by visiting https://protara-therapeutics-update-call.open-exchange.net/registration
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patientsFavorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsOn track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), including data from patients who have reached the 12-month evaluation timepoint. The data will be featured during an interactive poster session at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2
TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposuresFavorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse eventsCompany to host conference call and webcast today at
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, December 5, 2024, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology on December 5, 2024, at 1:15 p.m. CT. The live call can be accessed by registering as a participant here. Upo
Live Leadership Updates
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025 On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients in 4Q 2025 Cash, cash equivalents and investments of approximately $146 million as of June 30, 2025, expected to support planned operations into mid-2027 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage com
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. "Protara's inclusion in the Russell 3000® Index is a reflection of the progress that we have made executing across our pipeline, including the advancement of clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations and the development of our IV Choline Chlorid
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William "Bill" Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. "It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "With an impressive track record building commercial organizations and successfully launching oncology and rare disease prod
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies. "We are delighted to welcome Dr. Nicacio to the Protara team," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "As a proven leader with deep expertise spanning all stages of drug development, his guida
- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021 Expected to Fund Operations into Mid-2024 - NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. "Following a productive 2021, we are well poised to advance our pipeline in 2022, in particular, we are excited to have commenced our Phase 1 study of TARA-002 in non-muscle invasive b
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer. "We are thr
- Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End - - TARA-002 GMP Scale up and Comparability Ongoing and Expected to be Completed by Year-End - - Company Plans to Engage with FDA to Determine Clinical Trial Design for TARA-002 in Lymphatic Malformations - - Strong Cash, Cash Equivalents, and Investments Position of $145M as of June 30, 2021 - NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the se
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Jane Huang, M.D. to its Board of Directors. Dr. Huang, an experienced biotech executive and proven leader throughout the development lifecycle of multiple oncology therapeutics globally, currently serves as Chief Medical Officer, Hematology at BeiGene, Ltd. “It is a great privilege to welcome Dr. Huang to our Board of Directors,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “As a proven industry leader wi
- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End - - On Track to Complete TARA-002 GMP Scale up and Comparability in 2H, 2021 - - Plan to Engage with FDA and Initiate Clinical Study of TARA-002 in Lymphatic Malformations - - Strong Cash, Cash Equivalents and Investments Position of $155M as of March 31, 2021 - NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. "
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer, effective immediately. Dr. Olivo brings to Protara more than 15 years of experience in oncology translational and clinical research and global drug development, most recently serving as Vice President, Breast Cancer Clinical Development Lead at Gilead Sciences, Inc. (formerly Immunomedics, Inc.). "We are very excited to welcome Dr. Olivo to our leadership team," said Jesse Sheffer